dbio NEWS
  • Facebook - Black Circle
  • Twitter - Black Circle
  • YouTube - Black Circle

follow US



RSS Feed

Jacob Glanville on The Claman Countdown

Jake returned to the Claman Countdown on Fox Business to discuss the status of the pandemic, how new cases of coronavirus will continue to spike until we have a viable medicine or vaccine that can be made available to the entire world, and how our treatment is working in hamsters. Watch the clip here.

RNZ: Covid treatment study shows promising results in hamsters

A potential treatment for covid-19 is a step closer to reality with a promising study involving hamsters showing a 97% reduction of coronavirus in lungs within 48 hours of treatment. Dr Jacob Glanville head of US company Distributed Bio has been working on the development of an anti-body treatment with the aim to begin trials with humans around September. He spoke to me about how his technology works, and what the success of the hamster trial means. Listen to the episode here

Jake Glanville on Beyond the Molecule Podcast

Jacob Glanville is fascinated by the intersection of technology and medicine. Fueled by his experiences growing up in war-torn Guatemala, he wondered how he could use technology to create a post-pathogen world. Now, as CEO of Distributed Bio, he’s achieving that vision. In this episode, he explains the story behind his innovative universal vaccine tech, why he chose to leave a top job at a prestigious pharmaceutical company, and how he got to where he is today. Listen to the episode here.

Sarah Ives on Nick LaParra's Let's Give a Damn Podcast

In this episode of "Let's Give a Damn," with Nick LaParra, Sarah and Nick talk about her work on the universal flu vaccine and a coronavirus treatment, what it’s like to work on a cure that could change the world, her deep love for Guatemala, and more. Listen to the episode here.

Jake Glanville in Forbes

Link to original article by John Cumbers here. Jacob Glanville is an admirer of the human immune system — but he thinks we can do better. On Tuesday, his company Centivax announced that they have created optimized antibodies that protect hamsters from lethal amounts of the virus that causes COVID-19. Compared to animals that did not receive the antibody, treated hamsters were found to have 97 percent less virus in their lungs after 48 hours. This is a milestone for Centivax, which is among many companies trying to develop antibody treatments for COVID-19. Centivax’s antibodies are unique, however, in how they are made. Rather than using mammalian cells to produce a protein drug, which is com

Sarah Ives on LIVEMEDAID

On May 9, 2020 the scientific community came together for a first-of-its-kind, live-streamed event in support of Doctors Without Borders / MSF and front-line healthcare workers in the global fight against COVID-19. LIVEMEDAID brought together the world’s leading doctors, scientists, writers, thinkers, and cultural influencers to debate, collaborate, and share ideas about what we can learn from this virus, how to defeat it, and what we can expect as we move toward the future. Sarah's interview starts around the 2:00:00 mark. Visit their website for more information: https://livemedaid.com/

Jake Glanville on CGTN America

Jake chatted with Mark Niu of CGTN America over Skype to give an exciting update on how our antibodies have been proven to broadly neutralize the COVID-19 coronavirus in vitro by three different labs.



Distributed Bio in the news

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

BUSINESS WIRE | Oct 25, 2018

Distributed Bio's efforts to 

BUSINESS WIRE | Oct 25, 2018

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

BUSINESS WIRE | Oct 25, 2018

Distributed Bio Announces SuperHuman Platform Transfer to Kadmon

BUSINESS WIRE | Feb. 28, 2018

Pfizer, Boehringer sign JLABS resident Distributed Bio’s antibody discovery platform

FIERECE BIOTECH | Jan. 11, 2018

Distributed Bio Announces SuperHuman Platform License Agreement With Pfizer Inc.

BUSINESS WIRE | Jan. 5 2018

Distributed Bio, Inc. and Pandion Therapeutics, Inc. Announce Multi-Target Collaboration

BUSINESS WIRE | Dec. 12, 2017

Distributed Bio and Boehringer Ingelheim Announce SuperHuman Platform Transfer

BUSINESS WIRE | Dec. 11, 2017


All videos are free to view & download





All presentations are free to view & download







PEGS 2012


PEGS 2013





(415) 489-0246

201 Gateway Blvd, Floor 1

 South San Francisco, CA 94080, USA